Abstract: There are provided novel (2-imidazolin-2-yl) fused heteropyridine compounds, and intermediate compounds for the preparation thereof, and a method for controlling a wide variety of annual and perennial plant species therewith.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
July 16, 1996
Assignee:
American Cyanamid Co.
Inventors:
Barrington Cross, Marinus Los, Robert F. Doehner, Jr., David W. Ladner, Jerry L. Johnson
Abstract: Glycidyl esters are prepared to have low chlorine, chloride, sodium and potassium contamination and a thixotropic index greater than 3.0 by a process that comprises reacting carboxylic mono- or dimer acids with glycidyl alcohols in a molar ratio of 1 to (0.9-4.0) using carbodiimide as the acylating agent and a pyridine-type catalyst. The pyridine-type catalyst is removed by strongly acidic ion exchange resin.
Type:
Grant
Filed:
March 4, 1994
Date of Patent:
July 16, 1996
Assignee:
National Starch and Chemical Investment Holding Corporation
Abstract: There are provided novel (2-imidazolin-2-yl) fused heteropyridine compounds, and intermediate compounds for the preparation thereof, and a method for controlling a wide variety of annual and perennial plant species therewith.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
July 9, 1996
Assignee:
American Cyanamid Company
Inventors:
Barrington Cross, Marinus Los, Robert F. Doehner, Jr., David W. Ladner, Jerry L. Johnson
Abstract: This invention relates to a class of novel aliphatic amino bis-aryl compounds containing at least four carbon atoms and an amino group either substituted thereon or incorporated therein and is further linked or bridged to two mono- and/or bicyclic rings. Compounds of this invention reduce levels of serum cholesterol in the body without significantly reducing mevalonic metabolite synthesis. This invention relates also to pharmacological compositions and method of treatment for lowering serum cholesterol levels using the compounds of this invention.
Type:
Grant
Filed:
January 25, 1995
Date of Patent:
July 9, 1996
Assignee:
Rhone-Poulenc Rorer Pharmaceuticals Inc.
Inventors:
Robert A. Groneberg, John R. Regan, Kent W. Neuenschwander, Anthony C. Scotese
Abstract: There are provided novel (2-imidazolin-2-yl) fused heteropyridine compounds, and intermediate compounds for the preparation thereof, and a method for controlling a wide variety of annual and perennial plant species therewith.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
July 9, 1996
Assignee:
American Cyanamid Company
Inventors:
Barrington Cross, Marinus Los, Robert F. Doehner, Jr., David W. Ladner, Jerry L. Johnson
Abstract: There are provided novel (2-imidazolin-2-yl) fused heteropyridine compounds, and intermediate compounds for the preparation thereof, and a method for controlling a wide variety of annual and perennial plant species therewith.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
July 9, 1996
Assignee:
American Cyanamid Company
Inventors:
Barrington Cross, Marinus Los, Robert F. Doehner, Jr., David W. Ladner, Jerry L. Johnson
Abstract: The present invention provides a method of stabilizing solutions of 3-isothiazolone compounds using a stabilizing compound of the formula: ##STR1## wherein R is C.sub.1 -C.sub.6 alkyl; and compositions which comprise 3-isothiazolone compound, solvent and stabilizing compound.
Abstract: Production of a benzothiazole compound of the formula (I) ##STR1## wherein R.sup.1 is a halogen atom, R.sup.2 and R.sup.3 may be the same or different and each is a hydrogen atom or a halogen atom, R.sup.4 is a hydrogen atom, a halogen atom, a lower alkyl, an alkoxy or an alkyl mercapto and R.sup.5 is a hydrogen atom or a lower alkyl, or a pharmaceutically acceptable salt thereof.The compound of the formula (I) and a pharmaceutically acceptable salt thereof of the present invention have an aldose reductase inhibitory activity in mammals inclusive of human and have superior safety. Accordingly, they are useful as pharmaceutical compositions for the treatment of the complications of diabetes, such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, particularly cataract and neurosis.
Type:
Grant
Filed:
November 25, 1994
Date of Patent:
July 2, 1996
Assignees:
Senju Pharmaceutical Co., Ltd, The Green Cross Corporation
Abstract: There are provided novel (2-imidazolin-2-yl) fused heteropyridine compounds, and intermediate compounds for the preparation thereof, and a method for controlling a wide variety of annual and perennial plant species therewith.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
July 2, 1996
Assignee:
American Cyanamid Company
Inventors:
Barrington Cross, Marinus Los, Robert F. Doehner, Jr., David W. Ladner, Jerry L. Johnson
Abstract: As new antibiotics are obtained delaminomycins A, B and C having a formula (I) or (I') shown below, or salts thereof. Delaminomycins preferentially inhibit T cells and are useful as immunosuppressants, antineoplastic agents and antibacterial agents. ##STR1## wherein X is a hydroxyl group for delaminomycin A, a methoxy group for delaminomycin B and a hydrogen atom for delaminomycin C.
Type:
Grant
Filed:
January 20, 1995
Date of Patent:
June 18, 1996
Assignee:
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
Abstract: A process for the preparation of 1,2-benzisothiazoles of formula I ##STR1## wherein X is in any one of the 4 possible positions of the benzene ring and is hydrogen, halogen, nitro, C.sub.1 -C.sub.4 alkoxy, halo-C.sub.1 -C.sub.4 alkoxy, C.sub.2 -C.sub.4 alkenyloxy or C.sub.2 -C.sub.4 alkynyloxy, in which process a compound of formula II ##STR2## wherein X is as defined for formula I and R.sub.1 is hydrogen or an unsubstituted or substituted C.sub.1 -C.sub.12 hydrocarbon radical, is reacted in the presence of a catalytic amount of a strong acid.Compounds of formula I are known as pesticides, especially as nematicides.
Type:
Grant
Filed:
September 7, 1994
Date of Patent:
June 18, 1996
Assignee:
Ciba-Geigy Corporation
Inventors:
Hans-Ruedi Kanel, Arthur Wegmann, Denis Neff
Abstract: Organic compounds having at least one ethylenically-unsaturated group are described, the organic compounds being suitable for use in coatable compositions as reactive diluents; compounds of the invention preferably have a divalent organic linking moiety devoid of reactive groups other than optional ethylenically-unsaturated groups, and a polar organic moiety and are particularly adept in solubilizing aminoplast resins having radiation-curable pendant groups.
Type:
Grant
Filed:
November 4, 1994
Date of Patent:
June 4, 1996
Assignee:
Minnesota Mining and Manufacturing Company
Inventors:
Ernest L. Thurber, Eric G. Larson, Alan R. Kirk, Gregg D. Dahlke
Abstract: The present invention relates to synthetic intermediates useful for preparing amino acid derivatives possessing renin-inhibitory activity, and to processes for preparing the amino acid derivatives using the synthetic intermediates.
Abstract: There are provided substituted benzisoxazole and benzisothiazole compounds having the structural formula I ##STR1## Further provided are compositions and methods comprising those compounds for the control of undesirable plant species.
Abstract: The present invention relates to a novel 2-aminothiazolecarboxamide derivative represented by the following general formula (I): ##STR1## in which R.sup.1 -R.sup.5 are defined herein, which is a fungicidal agent useful for controlling phytopathogenic organisms. In addition, the present invention also relates to a process for preparing the novel 2-aminothiazolecarboxamide derivative of formula (I) and use of the compound of formula (I) as an agent for controlling phytopathogenic organisms.
Type:
Grant
Filed:
August 9, 1994
Date of Patent:
May 7, 1996
Assignee:
Lucky Ltd.
Inventors:
Yo S. Rew, Jinho Cho, Choon S. Ra, Sei-chang Ahn, Sung K. Kim, Yong-Hwan Lee, Bon Y. Jung, Woo B. Choi, Young H. Rhee, Man Y. Yoon, Sung W. Chun
Abstract: The invention concerns the compounds of formulae ##STR1## wherein the substituents have various significances. They can be prepared by various methods, e.g. acylation, reduction, alkylation, etc. They are indicated for use as pharmaceuticals, in particular as immunosuppressant, antiproliferative and antiinflammatory agents.